Cannabis oralmucosal spray does not significantly improve neuropathic pain from multiple sclerosis
How to Cite
OrthoEvidence. Cannabis oralmucosal spray does not significantly improve neuropathic pain from multiple sclerosis. ACE Report. 2018;7(10):46. Available from: https://myorthoevidene.com/AceReport/Report/10365
A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosisJ Neurol. 2013 Apr;260(4):984-97. doi: 10.1007/s00415-012-6739-4
Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
In a multicentre randomized trial, 339 patients with central neuropathic pain due to multiple sclerosis (MS) were randomized to receive either an oralmucosal spray containing THC and CBD (nabiximols) or placebo spray for 12 weeks, followed by an open-label and randomized-withdrawal phase for another 14 weeks. The primary outcome was at least 30% pain reduction, and secondary outcomes included time...
Continuing Medical Education Credits
You could be earning 0.5 CME credits for each report you read.LEARN MORE